vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above Fifty Day Moving Average – Here’s What Happened

vTv Therapeutics Inc. (NASDAQ:VTVT)’s share price passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $14.29 and traded as high as $16.90. vTv Therapeutics shares last traded at $16.43, with a volume of 14,424 shares trading hands.

vTv Therapeutics Trading Down 2.8 %

The company has a fifty day moving average of $14.29 and a 200-day moving average of $17.77. The company has a market capitalization of $49.45 million, a price-to-earnings ratio of -3.63 and a beta of 0.63.

Institutional Trading of vTv Therapeutics

A hedge fund recently bought a new stake in vTv Therapeutics stock. FMR LLC acquired a new stake in vTv Therapeutics Inc. (NASDAQ:VTVT) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 178,200 shares of the biotechnology company’s stock, valued at approximately $2,402,000. FMR LLC owned approximately 5.92% of vTv Therapeutics as of its most recent filing with the Securities and Exchange Commission. 17.51% of the stock is currently owned by institutional investors.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.